首页 bluebird bio(usBLUE)-基本信息

bluebird bio(usBLUE)-基本信息

日报更新时间:04-20 10:53

周报更新时间:04-18 04:06

行情信息

今开价:27.51

最高价:27.77

成交量:826511.0

昨收价:27.86

最低价:26.74

最新价:27.77

行情图标
概要信息

英文名称:bluebird bio


简介:bluebird bio, Inc.是一家临床阶段的生物技术公司,该公司利用基因治疗方法治疗严重遗传和罕见疾病来改变患者的生命


最新量化综合结论
百科信息
  • 相关网站
  • 员工交易记录
  • 持股信息
  • 领导人信息

交易日期 交易人 职位 类型 交易份额 价格
2019-08-05 Davidson (David) Officer Sell 900 117.77
2019-08-05 Davidson (David) Officer Sell 2960 115.25
2019-08-05 Davidson (David) Officer Sell 800 116.11
2019-08-05 Davidson (David) Officer Buy 5060 50.51
2019-08-05 Davidson (David) Officer Sell 400 118.44
2019-08-04 Gregory (Philip D) Officer Sell 750 116.79
2019-08-04 Gregory (Philip D) Officer Buy 600 50.51
2019-08-04 Gregory (Philip D) Officer Sell 100 118.01
2019-07-04 Davidson (David) Officer Buy 330 5.50
2019-07-04 Gregory (Philip D) Officer Buy 600 50.51
2019-07-04 Gregory (Philip D) Officer Sell 300 130.69
2019-07-04 Gregory (Philip D) Officer Sell 100 131.94
2019-07-04 Gregory (Philip D) Officer Sell 1089 128.27
2019-07-04 Gregory (Philip D) Officer Buy 700 75.60
2019-07-04 Gregory (Philip D) Officer Sell 311 129.70
2019-07-04 Davidson (David) Officer Sell 2828 128.28
2019-07-04 Davidson (David) Officer Sell 700 131.77
2019-07-04 Davidson (David) Officer Buy 7330 50.51
2019-07-04 Davidson (David) Officer Sell 3300 130.05
2019-07-04 Davidson (David) Officer Sell 832 129.32
2019-06-17 Walsh Jeffrey T Officer Sell 100 126.12
2019-06-17 Walsh Jeffrey T Officer Buy 100 24.47
2019-06-09 Walsh Jeffrey T Officer Sell 1200 125.19
2019-06-09 Walsh Jeffrey T Officer Buy 1400 24.47
2019-06-09 Walsh Jeffrey T Officer Sell 200 126.96

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
OppenheimerFunds Inc 892749 1.62% 85420 10.58% 2019-03-31
Vanguard Group Inc 4892714 8.88% 96157 2.00% 2019-03-31
Capital Research & Mgmt Co - Division 3 5119870 9.29% 69112 1.37% 2019-03-31
Fidelity Management & Research Company 5495240 9.94% -156594 -2.77% 2019-07-31
Capital Research Global Investors 6674436 12.11% -24995 -0.37% 2019-03-31
Wellington Management Company LLP 7311700 13.26% -80128 -1.08% 2019-03-31
FMR Inc 8242676 14.95% 38515 0.47% 2019-03-31
Fidelity Management and Research Company 8176776 14.83% 41515 0.51% 2019-03-31
Capital Research and Management Company 16122959 29.17% 348100 2.21% 2019-07-31
Baillie Gifford & Co Limited. 4479101 8.13% -50022 -1.10% 2019-03-31
Capital World Investors 4024783 7.30% 312002 8.40% 2019-03-31
BlackRock Inc 2980606 5.41% -5536 -0.19% 2019-03-31
Marshall Wace North America LP 951924 1.73% 951924 -- 2019-03-31
Vanguard Investments Australia Ltd 1148812 2.08% -385615 -25.13% 2019-07-31
State Street Corporation 1162241 2.11% 2355 0.20% 2019-03-31
Fidelity SelectCo, LLC 1171392 2.12% 63163 5.70% 2019-07-31
Hartford Funds Management Company, LLC 1435617 2.60% -2755 -0.19% 2019-07-31
T. Rowe Price Associates, Inc. 1535210 2.79% 263665 20.74% 2019-03-31
Fidelity Management Trust Co 2053191 3.71% -27900 -1.34% 2019-07-31
BlackRock Fund Advisors 2756547 4.99% -252631 -8.40% 2019-07-31
Bank of America Corporation 783225 1.42% 371053 90.02% 2019-03-31
Geode Capital Management, LLC 1105118 2.00% 595751 116.96% 2018-12-31
Deutsche Asset Management Investment GmbH 972624 1.76% 720908 286.40% 2019-05-31
Goldman Sachs Group Inc 699603 1.27% 240623 52.43% 2018-12-31
First Trust Advisors L.P. 601883 1.10% 233175 63.24% 2018-09-30
Bank of New York Mellon Corp 581695 1.06% 269074 86.07% 2018-09-30
BlackRock Institutional Trust Company NA 1333285 2.44% -21420 -1.58% 2018-06-30
Growth Fund of America Inc 2661153 5.42% 806350 43.47% 2017-12-29
State Street Corp 975963 1.94% -288009 -22.79% 2018-06-30
Goldman, Sachs & Co. 663990 1.32% 216246 48.30% 2018-06-30
Victory Capital Management Inc. 525192 1.05% -28660 -5.17% 2018-06-30
Orbimed Advisors, LLC 488200 0.97% 142600 41.26% 2018-06-30
Jennison Associates LLC 512740 1.02% 9677 1.92% 2018-06-30
Millennium Management LLC 446548 0.89% 446548 -- 2018-06-30
Franklin Advisers Inc 388400 0.77% 6900 1.81% 2018-06-30
Susquehanna Financial Group, LLLP 337635 0.67% 293985 673.51% 2018-06-30
Northern Trust Investments N A 592198 1.18% 2644 0.45% 2018-03-31
Charles Schwab Investment Management Inc 332536 0.66% 36463 12.32% 2018-03-31
Prudential Investments LLC 368493 0.74% -- -- 2018-05-31
NORGES BANK 398254 0.81% 26461 7.12% 2017-12-31
Lord, Abbett & Co LLC 357680 0.72% 110207 44.53% 2017-12-31
Two Sigma Investments LLC 462500 0.94% 447600 3004.03% 2017-12-31
Balyasny Asset Management LLC 503122 1.10% 113941 29.28% 2017-09-30
Eventide Asset Management, LLC 412000 0.90% -157700 -27.68% 2017-09-30
Arrowpoint Asset Management, LLC 361825 0.79% -68637 -15.94% 2017-09-30
Columbia Mangmt Investment Advisers, LLC 340199 0.74% 4182 1.24% 2017-09-30
RS Investment Management Co. LLC 475558 1.28% 55889 13.32% 2016-09-30
Entities affiliated with FMR LLC 4720878 4.00% 607199328 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Vanguard Small Cap Growth Index Fund 565293 1.02% -251285 -30.77% 2019-06-30
Vanguard Total Stock Market Index Fund 1136350 2.06% -385543 -25.33% 2019-06-30
American Funds American Balanced Fund 1480000 2.68% 245000 19.84% 2019-06-30
American Funds IS 1558700 2.82% -58400 -3.61% 2019-06-30
Fidelity Growth Company Commingled Pool 1931946 3.50% -27900 -1.42% 2019-06-30
American Funds SMALLCAP World Fund 1967720 3.56% -- -- 2019-06-30
American Funds New Economy Fund 2037064 3.69% 38300 1.92% 2019-06-30
Vanguard Health Care Fund 2815599 5.09% -- -- 2019-03-31
American Funds Growth Fund of Amer 5235960 9.47% 18000 0.34% 2019-06-30
American Funds Fundamental Invs 1113500 2.01% 105200 10.43% 2019-06-30
Vanguard Small Cap Index 985576 1.78% -448264 -31.26% 2019-06-30
T. Rowe Price Health Sciences Fund 620344 1.12% -65218 -9.51% 2019-06-30
First Trust NYSE Arca Biotech Fund 682734 1.24% -1645 -0.24% 2019-07-31
Fidelity 705765 1.28% -56700 -7.44% 2019-06-30
Vanguard Extended Market Index Fund 756599 1.37% -4811 -0.63% 2019-06-30
American Funds Capital World Gr&Inc Fd 857700 1.55% -- -- 2019-06-30
Scottish Mortgage Inv Tr 871592 1.58% -152341 -14.88% 2019-05-31
Hartford MidCap Fund 920092 1.66% 73000 8.62% 2019-06-30
American Funds New Perspective Fund 954300 1.73% -- -- 2019-06-30
Vanguard Small Cap Index Fund 1435305 2.60% 9226 0.65% 2019-04-30
iShares Russell 2000 ETF 1075051 1.96% 13320 1.25% 2018-06-21
VA CollegeAmerica Fundamental Inv 663900 1.21% 663900 -- 2018-12-31
VA CollegeAmerica The New Economy Fd 1987214 3.62% 51000 2.63% 2018-12-31
VA CollegeAmerica Capital Wld Gr & Inc 857700 1.56% 857700 -- 2018-12-31
VA CollegeAmerica SMALLCAP Wld Fd 2026270 3.69% 29400 1.47% 2018-12-31
iShares Nasdaq Biotechnology ETF 598986 1.09% -816 -0.14% 2019-02-26
VA CollegeAmerica New Perspective Fd 954300 1.74% 82800 9.50% 2018-12-31
VA CollegeAmerica Amer Blcd Fd 1205000 2.19% 1205000 -- 2018-12-31
VA CollegeAmerica The Gr Fd of Amer 5195960 9.46% 51100 0.99% 2018-12-31
SPDR 503817 0.92% -10890 -2.12% 2018-12-31
T. Rowe Price New Horizons Fund 721191 1.32% -11335 -1.55% 2018-09-30
VA CollegeAmerica Smcap World 529E 2106520 4.19% -- -- 2018-06-30
VA CollegeAmerica New Economy 529F 1442514 2.87% -666620 -31.61% 2018-06-30
Vanguard Total Stock Mkt Idx 1344821 2.48% 93412 7.46% 2018-07-31
T. Rowe Price Health Sciences 932281 1.86% 61900 7.11% 2018-06-30
Vanguard Small Cap Growth Index Inv 768590 1.42% 59306 8.36% 2018-07-31
T. Rowe Price New Horizons 732526 1.46% 59900 8.91% 2018-06-30
Hartford MidCap A 680597 1.26% 77696 12.89% 2018-07-31
VA CollegeAmerica New Perspective 529E 715000 1.42% 715000 -- 2018-06-30
Vanguard Extended Market Idx Inv 675292 1.25% 14377 2.18% 2018-07-31
iShares Nasdaq Biotechnology 568847 0.92% -1083 -0.19% 2018-09-12
Vanguard Health Care Inv 506578 1.01% 181150 55.67% 2018-06-30
Oppenheimer Global A 418399 0.77% -- -- 2018-07-31
First Trust NYSE Arca Biotech ETF 411704 0.67% -- -- 2018-09-13
VA CollegeAmerica Grth Fund of Amer 529F 3569336 7.11% 683020 23.66% 2018-06-30
Prudential Jennison Health Sciences A 368493 0.73% -- -- 2018-06-30
iShares Russell 2000 Value 336947 0.70% -555 -0.16% 2018-06-21
RS Small Cap Growth A 331327 0.89% 25239 8.25% 2016-09-30
Franklin Growth Fund A 400000 1.07% -- -- 2016-12-31
Vanguard Explorer Inv 377372 1.01% -134603 -26.29% 2016-09-30
Eventide Gilead N 417800 1.12% -- -- 2016-09-30
VA CollegeAmerica Growth Fund of America 2056187 5.60% 2056187 -- 2015-09-30
VA CollegeAmerica Small Cap World 1588565 4.30% -167000 -9.50% 2015-09-30
VA CollegeAmerica New Economy 882372 2.40% 29990 3.50% 2015-09-30
American Funds IS® Gbl Sm Cap 800169 2.20% -113490 -12.40% 2015-09-30
Fidelity® Series Growth Company Fund 603181 1.60% 4900 0.80% 2015-09-30
Oppenheimer Global Fund 570424 1.60% 41890 7.90% 2015-09-30
Fidelity® Contrafund® Fund 507347 1.40% -233 -- 2015-09-30
American Funds NVIT Growth 428000 1.20% -- -- 2015-09-30
Fidelity® Growth Company Fund 2233470 6.10% -5800 -0.30% 2015-09-30

Wendy L. Dixon Wendy L. Dixon is Chairman at Sesen Bio, Inc. and President for Great Meadow Consulting LLC. She is also on the board of 5 other companies. In the past she held the position of Principal at West Pharmaceutical Services, Inc., Senior Vice President & President-Marketing at Merck & Co., Inc., Chief Marketing Officer for Bristol-Myers Squibb Co., Principal at Centocor, Inc., Senior Advisor at The Monitor Group, Inc., Principal at Osteotech, Inc. and Principal at Smithkline & French Laboratories US, Inc. Wendy L. Dixon received a graduate degree, a doctorate and an undergraduate degree from the University of Cambridge.
Philip D. Gregory Presently, Philip D. Gregory holds the position of Chief Scientific Officer at bluebird bio, Inc. Dr. Gregory is also on the board of American Society of Gene & Cell Therapy. Dr. Gregory previously occupied the position of Chief Scientific Officer & Senior VP-Research at Sangamo Therapeutics, Inc. and Senior Vice President-Operations for Flextronics Components Group. Dr. Gregory received a doctorate from the University of Oxford and an undergraduate degree from The University of Sheffield.
Joanne M. Smith-Farrell Joanne M. Smith-Farrell is Chief Business Officer for bluebird bio, Inc. In the past she held the position of Vice President-Strategic Transactions at Pfizer Inc., Senior Vice President-Business Development for Gene Logic, Inc. and Vice President-Business Development Transactions at Merck, Inc. She received a doctorate from The Catholic University of America and an undergraduate degree from Vanderbilt University.
Mary Lynne Hedley Mary Lynne Hedley founded TESARO, Inc. and Zycos, Inc. She is on the board of Millendo Therapeutics US, Inc., bluebird bio, Inc., Youville Place and Millendo Therapeutics, Inc. Dr. Hedley previously was President & Chief Executive Officer at Zycos, Inc., President, Chief Operating Officer & Director at TESARO, Inc., Chief Scientific Officer & Executive VP at MGI PHARMA, Inc., Chief Scientific Officer & EVP-Operations at Abraxis BioScience, Inc., General Manager & Senior Vice President at MGI PHARMA Biologics, Inc. and Executive Vice President at Eisai Corp. of North America. Dr. Hedley received an undergraduate degree from Purdue University and a doctorate from The University of Texas Southwestern Medical Center.
Jason F. Cole Jason F. Cole occupies the position of Chief Operating & Legal Officer at bluebird bio, Inc. He previously occupied the position of Attorney-Corporate & Securities at Ropes & Gray LLP, Secretary & Executive VP-Corporate Development at Zalicus, Inc., Secretary, Senior Vice President & General Counsel at Neuromed Pharmaceuticals, Inc. and Secretary, Senior Vice President & General Counsel at CombinatoRx, Inc. He received an undergraduate degree from Dartmouth College and a graduate degree from Columbia Law School.
Douglas A. Melton Douglas A. Melton is an entrepreneur who founded Gilead Sciences, Inc., Curis, Inc., Harvard Stem Cell Institute and Semma Therapeutics, Inc. Currently, Dr. Melton occupies the position of Faculty Director at Harvard Stem Cell Institute. He is also on the board of bluebird bio, Inc. and Semma Therapeutics, Inc. and Member of National Academy of Sciences, Member of The International Society for Stem Cell Research and Professor at Harvard University. In the past Douglas A. Melton occupied the position of Director at Curis, Inc. Dr. Melton received an undergraduate degree from the University of Illinois and a doctorate and an undergraduate degree from the University of Cambridge.
Daniel S. Lynch Daniel S. Lynch is a businessperson who has been at the head of 14 different companies. Presently, Mr. Lynch occupies the position of Chairman for Translate Bio, Inc., Chairman of bluebird bio, Inc., Executive Chairman for Blueprint Medicines Corp., Executive Chairman of Surface Oncology, Inc., Executive Chairman of SpringWorks Therapeutics LLC and Executive Chairman at Proclara Biosciences, Inc. Mr. Lynch is also on the board of Sesen Bio, Inc. (former Chairman). Mr. Lynch previously was Chairman of DNIB Unwind, Inc., Executive Chairman at Nimbus Therapeutics LLC, Executive Chairman for eGenesis, Inc., President & Chief Executive Officer at Ivrea Pharmaceuticals, Inc., Vice President-Finance at Bristol-Myers Squibb Co., Vice President-Finance of US Pharmaceuticals, Inc., Entrepreneur-in-Residence at Third Rock Ventures LLC, Executive Chairman of Avila Therapeutics, Inc., Chairman of Stromedix, Inc., Chief Executive & Financial Officer for ImClone LLC and Chief Financial Officer of Derby Cycle Corp. He received an undergraduate degree from Wesleyan University and an MBA from the University of Virginia Darden School of Business.
David Paul Schenkein David Paul Schenkein holds the position of Executive Chairman for Agios Pharmaceuticals, Inc., Venture Partner at ARCH Venture Partners LLC and General Partner at GV Management Co. LLC. Dr. Schenkein is also on the board of Biotechnology Innovation Organization, bluebird bio, Inc. and Denali Therapeutics, Inc. In his past career he occupied the position of Senior Vice President-Clinical Research at Takeda Oncology Co., Senior Vice President-Oncology Development at Genentech, Inc. and Associate Professor at Tufts Medical Center, Inc. David Paul Schenkein received an undergraduate degree from Wesleyan University and a doctorate from SUNY Upstate Medical University.
Mark L. Vachon Mark L. Vachon is Member of Metropolitan Milwaukee Association of Commerce and Member of Center for Corporate Innovation, Inc. and on the board of 6 other companies. In his past career he was Principal at NBC General Electric, Chief Executive Officer-Global Diagnostics Imaging at GE Healthcare, Inc., Chief Financial Officer & Executive Vice President of GE Healthcare Ltd., Principal at General Electric Appliances, Inc., Principal at GE Plastics Europe and Executive Vice President-Sales at Change Healthcare Holdings, Inc. Mr. Vachon received an undergraduate degree from Northeastern University.
Kathleen Wilkinson Presently, Kathleen Wilkinson holds the position of Chief People Officer for bluebird bio, Inc. Ms. Wilkinson previously was Operations Director of Adnexus. Ms. Wilkinson received an undergraduate degree from Harvard University.
Jeffrey T. Walsh Presently, Jeffrey T. Walsh holds the position of Chief Strategy Officer at bluebird bio, Inc. Mr. Walsh is also on the board of Tevard Biosciences, Inc. and Treasurer & Director at Alliance for Regenerative Medicine. In his past career he occupied the position of Principal at GlaxoSmithKline Plc, Vice President-Business Development at EXACT Sciences Corp., Senior Director-Corporate Finance at PathoGenesis Corp, Vice President-Business Development at Allscripts LLC, Chief Business Officer & Executive Vice President at Inotek Pharmaceuticals Corp. and Chief Business Officer for Taligen Therapeutics, Inc. Mr. Walsh received an undergraduate degree from Yale University and an MBA from Kellogg School of Management.
Nick Leschly Founder of Medxtend Corp., Nick Leschly presently holds the position of President, Chief Executive Officer & Director at bluebird bio, Inc. and Chief Executive Officer at FierceBiotech. He is also on the board of Biotechnology Innovation Organization, Proclara Biosciences, Inc., Synlogic Operating Co., Inc. and Synlogic, Inc. In the past he was Chief Executive Officer for Medxtend Corp., Partner at Third Rock Ventures LLC and Chief Business Officer of Agios Pharmaceuticals, Inc. He received an undergraduate degree from Princeton University and an MBA from The Wharton School of the University of Pennsylvania.
Philip D. Gregory Presently, Philip D. Gregory holds the position of Chief Scientific Officer at bluebird bio, Inc. Dr. Gregory is also on the board of American Society of Gene & Cell Therapy. Dr. Gregory previously occupied the position of Chief Scientific Officer & Senior VP-Research at Sangamo Therapeutics, Inc. and Senior Vice President-Operations for Flextronics Components Group. Dr. Gregory received a doctorate from the University of Oxford and an undergraduate degree from The University of Sheffield.
Alison C. Finger Alison C. Finger is on the board of Regenerative Medicine Foundation and Chief Commercial Officer for bluebird bio, Inc. In the past Ms. Finger was Managing Director at Bristol-Myers Squibb Pharmaceuticals Ltd. Ms. Finger received an undergraduate degree from St. Lawrence University and an MBA from The Fuqua School of Business.
William Denise Baird Mr. William D. Baird is a Chief Financial Officer at bluebird bio, Inc. and an Independent Director at Axcella Health, Inc. He is on the Board of Directors at Axcella Health, Inc. and Amicus Therapeutics UK Ltd. Mr. Baird was previously employed as a Chief Financial Officer by Amicus Therapeutics, Inc., a Chief Financial Officer by PTC Therapeutics, Inc., and an Engagement Manager by LEK Consulting, Inc. He received his undergraduate degree from Edmund A. Walsh School of Foreign Service and an MBA from The Wharton School of the University of Pennsylvania.
David M. Davidson Presently, David M. Davidson is Chief Medical Officer for bluebird bio, Inc. and Chief Executive Officer at Podiatry Affiliates, PC. In his past career Dr. Davidson occupied the position of Senior Medical Director at Genzyme Corp. and Medical Director of GelTex Pharmaceuticals, Inc. He received an undergraduate degree from Columbia University and a doctorate from New York University School of Medicine.
Kathleen Wilkinson Presently, Kathleen Wilkinson holds the position of Chief People Officer for bluebird bio, Inc. Ms. Wilkinson previously was Operations Director of Adnexus. Ms. Wilkinson received an undergraduate degree from Harvard University.
Philip D. Gregory Dr. Philip D. Gregory is a Chief Scientific Officer at bluebird bio, Inc. Dr. Gregory was previously employed as a Chief Scientific Officer & Senior VP-Research by Sangamo BioSciences, Inc. and a Senior Vice President-Operations by Flextronics Components Group. He received his undergraduate degree from The University of Sheffield and a doctorate degree from the University of Oxford.
John O. Agwunobi John O. Agwunobi is on the board of Oration PBC, bluebird bio, Inc., US African Development Foundation and Smart Rx Systems, Inc. and Co-President, Chief Health & Nutrition Officer at Herbalife Nutrition Ltd. Dr. Agwunobi previously occupied the position of Secretary-Health Department at State of Florida, Senior Vice President, President-Health & Wellness at Walmart, Inc. and Assistant Secretary at US Department of Health & Human Services (DC). Dr. Agwunobi received a graduate degree from The Johns Hopkins University and an MBA from Georgetown University.
Mark L. Vachon Mr. Mark L. Vachon is a Member at Metropolitan Milwaukee Association of Commerce and a Member at Center for Corporate Innovation. He is on the Board of Directors at Numotion, bluebird bio, Inc., Advanced Medical Technology Association, Medical Imaging Technology Associates, and Northeastern University. Mr. Vachon was previously employed as Chief Financial Officer & Executive Vice President by GE Healthcare Ltd., President & Chief Executive Officer by GE Healthcare, Inc., a Principal by GE Plastics Europe, a Principal by General Electric Appliances, Inc., and a Principal by NBC General Electric. He received his undergraduate degree from Northeastern University.
Mark L. Vachon Mark L. Vachon is Member of Metropolitan Milwaukee Association of Commerce and Member of Center for Corporate Innovation, Inc. and on the board of 6 other companies. In his past career he was Principal at NBC General Electric, Chief Executive Officer-Global Diagnostics Imaging at GE Healthcare, Inc., Chief Financial Officer & Executive Vice President of GE Healthcare Ltd., Principal at General Electric Appliances, Inc., Principal at GE Plastics Europe and Executive Vice President-Sales at Change Healthcare Holdings, Inc. Mr. Vachon received an undergraduate degree from Northeastern University.
Derek Adams Presently, Derek Adams is Chief Technology & Manufacturing Officer at bluebird bio, Inc. In the past Dr. Adams held the position of VP-Technical & Strategic Product Development at Alexion Pharmaceuticals, Inc. and Senior Vice President-CMC at Evelo Biosciences, Inc. Dr. Adams received a doctorate from the University of Minnesota and an undergraduate degree from Worcester Polytechnic Institute.
M. Travis Quigley M. Travis Quigley is Senior Director-Clinical Development at bluebird bio, Inc.
Mohammed Asmal Mohammed Asmal is Vice President-Clinical Development at bluebird bio, Inc.
Kory James Wentworth Kory James Wentworth is Treasurer & Chief Accounting Officer at bluebird bio, Inc. In the past he occupied the position of Executive Director & Corporate Controller at Alexion Pharmaceuticals, Inc. Mr. Wentworth received an undergraduate degree from Susquehanna University.
Elizabeth Pingpank Presently, Elizabeth Pingpank is Director-Corporate Communications at bluebird bio, Inc.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐